BridgeBio Oncology Therapeutics Inc (BBOT) Price Prediction & ForecastBBOTBridgeBio Oncology Therapeutics Inc

Alphio's BBOT stock price prediction model matches the current BridgeBio Oncology Therapeutics Inc tape against historical breakout patterns, then publishes 1-day and 1-week targets first. The 1-day print is $8.68 (-0.74%). The 1-week path is $8.83 (+1.08%). Longer windows use the same pattern set plus seasonality; the 1-month and multi-year forecasts sit behind unlock because they include precise min / avg / max bands.

Helix Acquisition Corp II (BBOT) is not a good buy right now due to its current price of $8.74, which is significantly below analyst price targets ranging from $22 to $29. The stock has a low RSI of 33.785, indicating it is oversold, but the negative catalysts such as a consistent decline in net income and a projected EPS of -0.71 suggest ongoing financial struggles. The main risk is the high forward P/E ratio of 0, indicating uncertainty in future earnings.

BridgeBio Oncology Therapeutics Inc (BBOT) last closed at $8.74, losing -4.79%. These facts feed the 1-day and 1-week BBOT price prediction above.